Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy

Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy Publisher Pubmed

Ramezani F^{1, 2} ; Panahi Meymandi AR³ ; Akbari B³ ; Tamtaji OR^{4, 5} ; Mirzaei H⁶ ; Brown CE^{7, 8} ; Mirzaei HR^{3, 9}

Show Affiliations

1. Division of Medical Biotechnology, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2. Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
7. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, United States
8. Department of Immuno-Oncology, City of Hope Beckman Research Institute, Duarte, CA, United States
9. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, United States

Source: Molecular Cancer Published:2023

Abstract

Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review, we explore the role of trogocytosis in CAR NK/T cell therapy and highlight potential strategies for its modulation to improve therapeutic efficacy. We provide an in-depth analysis of trogocytosis as it relates to the fate and function of NK and T cells, focusing on its effects on cell activation, cytotoxicity, and antigen presentation. We discuss how trogocytosis can mediate transient antigen loss on cancer cells, thereby negatively affecting the effector function of CAR NK/T cells. Additionally, we address the phenomenon of fratricide and trogocytosis-associated exhaustion, which can limit the persistence and effectiveness of CAR-expressing cells. Furthermore, we explore how trogocytosis can impact CAR NK/T cell functionality, including the acquisition of target molecules and the modulation of signaling pathways. To overcome the negative effects of trogocytosis on cellular immunotherapy, we propose innovative approaches to modulate trogocytosis and augment CAR NK/T cell therapy. These strategies encompass targeting trogocytosis-related molecules, engineering CAR NK/T cells to resist trogocytosis-induced exhaustion and leveraging trogocytosis to enhance the function of CAR-expressing cells. By overcoming the limitations imposed by trogocytosis, it may be possible to unleash the full potential of CAR NK/T therapy against cancer. The knowledge and strategies presented in this review will guide future research and development, leading to improved therapeutic outcomes in the field of immunotherapy. © 2023, The Author(s).

Related Docs

View other Related Docs

1. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)

2. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)

3. The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence, Journal of Bone Oncology (2024)

4. Applications of Single-Cell Omics for Chimeric Antigen Receptor T Cell Therapy, Immunology (2024)

5. A Deep Insight Into Crispr/Cas9 Application in Car-T Cell-Based Tumor Immunotherapies, Stem Cell Research and Therapy (2021)

6. Targeted Knockdown of Tim3 by Short Hairpin Rnas Improves the Function of Anti-Mesothelin Car T Cells, Molecular Immunology (2021)

7. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)

8. Epigenetic Strategies to Boost Car T Cell Therapy, Molecular Therapy (2021)

Experts (# of related papers)

View all Related Experts

Hamid Reza Mirzaei (12)

Jamshid Hadjati (8)

Style	Citing Format
MLA	Ramezani F, et al.. "Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy." Molecular Cancer, vol. 22, no. 1, 2023, pp. -.
APA	Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, Mirzaei HR (2023). Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy. Molecular Cancer, 22(1), -.
Chicago	Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, Mirzaei HR. "Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy." Molecular Cancer 22, no. 1 (2023): -.
Harvard	Ramezani F et al. (2023) 'Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy', Molecular Cancer, 22(1), pp. -.
Vancouver	Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, et al.. Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy. Molecular Cancer. 2023;22(1):-.
BibTex	@article{ author = {Ramezani F and Panahi Meymandi AR and Akbari B and Tamtaji OR and Mirzaei H and Brown CE and Mirzaei HR}, title = {Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy}, journal = {Molecular Cancer}, volume = {22}, number = {1}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Ramezani F AU - Panahi Meymandi AR AU - Akbari B AU - Tamtaji OR AU - Mirzaei H AU - Brown CE AU - Mirzaei HR TI - Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy JO - Molecular Cancer VL - 22 IS - 1 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract